News
Article
Author(s):
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 23, 2024.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The director of Dysautonomia Clinic talked about the importance of focusing beyond migraine to address often overlooked comorbidities such as dysautonomia, hypermobility spectrum disorders, and mast cell activation syndrome. [WATCH TIME: 10 minutes]
This publication presents a collection of insights and takeaways from presentations with the goal of bridging the gaps between new developments and their application in practice for multiple sclerosis.
The medical director of the Cooper Neurological Institute and the professor of neurology at Yale University School of Medicine shared a few highlights from research presented at ISC 2024. [WATCH TIME: 7 minutes]
In this week's NeuroVoices Q&A, the professor in the Department of Translational Neuroscience at Barrow Neurological Institute discussed several topics related to ALS research and the emerging biomarkers in recent years ahead of the 2024 MDA Clinical and Scientific Conference.
In a new episode of the "CMSC Consensus Panel Guidance on the Use of Serum Neurofilament Light Chain in the Management of Multiple Sclerosis" video series, Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, contextualize data from large studies regarding the utilization of neurofilament light chain.